[1]李苑硕　卢昌均　邓春蕾　刘黎敏.血管性痴呆外周血生物标志物的研究进展[J].大众科技,2022,24(04):121-125.
　Research Progress in Peripheral Blood Biomarkers of Vascular Dementia[J].Popular Science & Technology,2022,24(04):121-125.
点击复制

血管性痴呆外周血生物标志物的研究进展()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
24
期数:
2022年04
页码:
121-125
栏目:
医药与卫生
出版日期:
2022-04-20

文章信息/Info

Title:
Research Progress in Peripheral Blood Biomarkers of Vascular Dementia
作者:
李苑硕1　卢昌均2　邓春蕾1　刘黎敏1　
（1.广西中医药大学，广西 南宁 530001；2.广西中医药大学第三附属医院，广西 柳州 545000）
关键词:
血管性痴呆; 生物标志物; 诊断
Keywords:
vascular dementia biomarkers diagnosis
文献标志码:
A
摘要:
血管性痴呆（VD）是唯一可预防的痴呆，早期诊断在VD的研究领域中占据重要地位。目前，VD的诊断多建立在临床资料、认知功能测试的综合基础上，缺乏客观的血清学生物标志物，故筛查VD相关的生物标志物具有一定的临床意义及科研价值，文章对近年来的VD外周血生物标志物研究进展进行简要综述。
Abstract:
Vascular dementia (VD) is the only preventable dementia, and early diagnosis plays an important role in the research field of VD. At present, the diagnosis of VD is mostly based on the comprehensive clinical data and cognitive function testing, and there is a lack of objective serological biomarkers. Therefore, the screening for biomarkers related to VD has certain scientific research value and clinical significance. This paper briefly summarizes the research progress of VD peripheral blood biomarkers in recent years.

参考文献/References:

[1]　贾建平，王树英. 血管性痴呆临床诊断标准探讨[J]. 中国神经免疫学和神经病学杂志，2010(6): 387-389. [2]　Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study[J]. Lancet Public Health, 2020, 5(12): e661-e671. [3]　刘娟，崔佳. 血管性痴呆病人血清可溶性凋亡相关因子及其配体、脑源性神经营养因子水平变化[J]. 中西医结合心脑血管病杂志，2021，19(11): 1902-1904. [4]　Aberg N D, Wall A, Anger O, et al. Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome[J]. Acta Neurologica Scandinavica, 2020, 141(5): 13219. [5]　李薇薇，谢渭根. 白细胞介素在血管性痴呆并糖耐量减低患者中的应用分析[J]. 重庆医学，2020，49(9): 1492-1495. [6]　Zuliani G, Guerra G, Ranzini M, et al. High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia[J]. International Journal of Geriatric Psychiatry, 2007, 22(4): 305-311. [7]　李宗阳，倪敬年，魏明清，等. 阿尔茨海默病和血管性痴呆患者外周炎症因子差异性的Meta分析[J]. 中国循证医学杂志，2021，21(5): 578-585. [8]　Malhotra S, Costa C, Eixarch H, et al. NLRP3 inflammas ome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients[J]. Brain, 2020, 143(5): 1414-1430. [9]　Dai Z, Jiao Y, Fan Q, et al. Homocysteine, interleukin-1β, and fasting blood glucose levels as prognostic markers for diabetes mellitus complicated with cerebral infarction and correlated with carotid intima-media thickness[J]. Experimental and Therapeutic Medicine, 2020, 19(2): 8326. [10] 李建瑞，马冉冉，樊新红，等. 血清MDA、SOD、IL-1β、IFN-γ在血管性痴呆中的表达及与神经功能、预后的关系[J]. 海南医学，2020，31(4): 433-437. [11] 许超，王鹏，陈育松，等. 炎症相关因子对血管性痴呆患者继发癫痫的影响及预测价值分析[J]. 心电与循环，2021，40(1):53-56，77. [12] Qi F, Hu Y, Li Y, et al. Levels of anti-oxidative molecules and inflammatory factors in patients with vascular dementia and their clinical significance[J]. Pakistan Journal of Medical Sciences, 2021, 37(5): 1509-1513. [13] Hsu P, Pan W, Yip B, et al. C-reactive protein predicts incidence of dementia in an elderly Asian community cohort[J]. Journal of the American Medical Directors Association, 2017, 18(3): e277. [14] Cozachenco D, Selles M C, Ribeiro F C, Interferon-γ as a potential link between diabetes mellitus and dementia[J]. Journal of Neuroscience, 2019, 39: 4632-4635. [15] Ta T T, Dikmen H O, Schilling S, et al. Priming of microglia with IFN-γ slows neuronal gamma oscillations in situ[J]. Proceedings of the National Academy of Sciences, 2019, 116(10): 4637-4642. [16] 郝美美，李晨曦. 血清Livin、IFN-γ水平在血管性痴呆患者中的变化及其临床意义[J]. 卒中与神经疾病，2018，25(6): 668-671，680. [17] Suridjan I, Herrmann N, Adibfar A, et al. Lipid peroxidation markers in coronary artery disease patients with possible vascular mild cognitive impairment[J]. Journal of Alzheimers Disease, 2017, 58(3): 885-896. [18] Liu Z, Liu Y, Tu X, et al. High serum levels of malondialdehyde and 8-OHdG are both associated with early cognitive impairment in patients with acute ischaemic stroke[J]. Scientific Reports, 2017, 7(1): 9493. [19] 朱红敏，章军建，杨英. DNA氧化性损伤标志物8-羟基脱氧鸟苷在阿尔茨海默病和血管性痴呆患者血浆中的变化[J]. 中华老年医学杂志，2013，32(11): 1164-1168. [20] Kartavenka K, Panuwet P, Yakimavets V, et al. LC-MS quantification of malondialdehyde-dansylhydrazine derivatives in urine and serum samples[J]. Journal of Analytical Toxicology, 2020, 44(5): 470-481. [21] Gustaw-Rothenberg K, Kowalczuk K, Stryjecka-Zimmer M. Lipids peroxidation markers in Alzheimers disease and vascular dementia[J]. Geriatrics and Gerontology International, 2010, 10(2): 161-166. [22] 李建瑞，马冉冉，樊新红，等. 血清MDA、SOD、IL-1β、IFN-γ在血管性痴呆中的表达及与神经功能、预后的关系[J]. 海南医学，2020，31(4): 433-437. [23] Taler-Ver??A, Goli?ik M, Bavec A. The structure and function of paraoxonase-1 and its comparison to paraoxonase-2 and -3[J]. Molecules, 2020, 25(24): 5980. [24] 徐新蕾，蔡德亮. 氧化应激指标与血管性痴呆的关系研究[J]. 中国全科医学，2012，15(33): 3887-3889. [25] Cervellati C, Trentini A, Romani A, et al. Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: a pilot study[J]. Journal of Neurochemistry, 2015, 135(2): 395-401. [26] Li K, Jia J, Wang Z, et al. Elevated serum levels of NSE and S-100β correlate with increased risk of acute cerebral infarction in Asian populations[J]. Medical Science Monitor, 2015, 21: 1879-1888. [27] 刘森，郭园园，胡敬，等. 脑梗死后血管性痴呆患者血浆HCV、S100β蛋白水平变化及意义[J]. 山东医药，2016，56(29): 58-60. [28] Shi S, Wang G, Zhang K, et al. Expression of S100β protein in patients with vascular dementia after basal ganglia hemorrhage and its clinical significance[J]. Experimental and Therapeutic Medicine, 2017, 13(5): 1917-1921. [29] Shen Y, Gao H M. Serum somatostatin and neuron-specific enolase might be biochemical markers of vascular dementia in the early stage[J]. International journal of clinical and experimental medicine, 2015, 8(10): 19471-19475. [30] Bergman J, Dring A, Zetterberg H, et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS[J]. Neurology: Neuroimmunology and Neuroinflammation, 2016, 3(5): e271. [31] Ma W, Zhang J, Xu J, et al. Elevated levels of serum neurofilament light chain associated with cognitive impairment in vascular dementia[J]. Disease Markers, 2020, 2020: 6612871. [32] Phillips C. Brain-derived neurotrophic factor, depression, and physical activity: making the neuroplastic connection[J]. Neural Plasticity, 2017, 2017: 7260130. [33] Ventriglia M, Zanardini R, Bonomini C, et al. Serum brain-derived neurotrophic factor levels in different neurological diseases[J]. BioMed Research Internationa, 2013, 2013: 901082. [34] 刘娟，崔佳. 血管性痴呆病人血清可溶性凋亡相关因子及其配体、脑源性神经营养因子水平变化[J]. 中西医结合心脑血管病杂志，2021，19(11): 1902-1904. [35] Shi D, Han M, Liu W, et al. Circulating microRNAs as diagnostic biomarkers ofclinical cognitive impairment: a meta-analysis[J]. American Journal of Alzheimers Disease and other Dementias, 2020, 35: 1686. [36] Qian Y, Song J, Ouyang Y, et al. Advances in roles of miR-132 in the nervous system[J].?rontier in Pharmacology. 2017, 8:770. [37] Huang S, Zhao J, Huang D, et al. Serum miR-132 is a risk marker of post-stroke cognitive impairment[J]. Neuroscience Letters, 2016，615: 102-106. [38] Chen L, Dong R, Lu Y, et al. MicroRNA-146a protects against cognitive decline induced by surgical trauma by suppressing hippocampal neuroinflammation in mice[J]. Brain, Behavior, and Immunity, 2019, 78: 188-201. [39] Dong H, Li J, Huang L, et al. Serum microRNA profiles serve as novel biomarkers for the diagnosis of Alzheimers disease[J]. Disease Markers, 2015, 2015: 625659. [40] Zhao F, Zhao H, Fan J, et al. MiR-29a knockout aggravates neurological damage by pre-polarizing M1 microglia in experimental rat models of acute stroke[J]. Frontiers in Genetics, 2021, 12: 642079. [41] Ragusa M, Bosco P, Tamburello L, et al. miRNAs plasma profiles in vascular dementia: biomolecular data and biomedical implications[J]. Frontiers in Cellular Neuroscience, 2016, 10: 51. [42] Barbagallo C, Mostile G, Baglieri G, et al. Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases[J]. Cellular and Molecular Neurobiology, 2020, 40(4): 531-546.

相似文献/References:

[1]李伟茜 唐 农 王晋平 莫斯思.血管性痴呆的中医病因病机研究进展[J].大众科技,2015,15(03):105.
[2]覃 辉 张永全 谭文澜 陆 晖.复脑灵方对血管性痴呆大鼠模型的 学习记忆能力的影响[J].大众科技,2018,20(10):54.
　Effects of Funaolingfang on Learning and Memory Ability in Vascular Dementia Rat[J].Popular Science & Technology,2018,20(04):54.
[3]张 新 李笑微 李 亨 屈 瑞.毫针刺治疗血管性痴呆的选穴规律研究[J].大众科技,2023,25(9):54.
　Study on the Rule of Acupoint Selection in the Treatment of Vascular Dementia with Acupuncture[J].Popular Science & Technology,2023,25(04):54.
[4]王 瑞 方 兴 张兴棠.中医药治疗血管性痴呆的研究进展[J].大众科技,2022,24(01):85.
　Research Progress of Traditional Chinese Medicine in the Treatment of Vascular Dementia[J].Popular Science & Technology,2022,24(04):85.
[5]蒋利明.康复治疗对老年血管性痴呆患者认知功能障碍影响研究[J].大众科技,2022,24(01):89.
　Study on the Effect of Rehabilitation Therapy on Cognitive Dysfunction in Elderly Patients with Vascular Dementia[J].Popular Science & Technology,2022,24(04):89.
[6]王梓塨 邱 华 朱玟霜 李 旺 蒙荫杰 王倩倩.细胞外囊泡在肝纤维化进展中的作用机制及临床意义[J].大众科技,2022,24(12):61.
　Mechanism and Clinical Significance of Extracellular Vesicles in the Progression of Hepatic Fibrosis[J].Popular Science & Technology,2022,24(04):61.
[7]卢美住 卢昌均.艾灸治疗血管性痴呆的研究进展[J].大众科技,2022,24(11):64.
　Research Progress in Moxibustion Treatment of Vascular Dementia[J].Popular Science & Technology,2022,24(04):64.
[8]蒋灿灿　周淑萍　陈紫君　盛晓曼.关于胃癌相关非侵入性生物标志物的研究进展[J].大众科技,2023,25(3):112.
　Research Progress of Non-Invasive Biomarkers Related to Gastric Cancer[J].Popular Science & Technology,2023,25(04):112.

备注/Memo

备注/Memo:
【收稿日期】2022-01-17 【作者简介】李苑硕（1993－），女，广西中医药大学在读硕士研究生，住院医师，研究方向为脑血管疾病基础与临床；卢昌均（1963－），男，广西中医药大学第三附属医院柳州市中医医院主任医师，博士，研究方向为脑血管疾病基础与临床。
更新日期/Last Update: 2022-07-12